TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03567408

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Selective PCI
Description: Selective PCI for treatment of elderly patients (age≥65) presenting with diabetes mellitus.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Selective PCI
Description: Selective PCI for treatment of elderly patients (age≥65) presenting with diabetes mellitus.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Description: Before, during and after surgery, bivalirudin was used according to the dosage regimen to assess it's impact on elderly patients with diabetes mellitus undergoing selective PCI.
Study: NCT02512887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caudal Block Anesthesia
Description: Anesthesia will be delivered via inhalation induction with air/nitrous oxide and sevoflurane, and injection of 0.25% bupivacaine 1mL/kg without epinephrine into the caudal canal, which is the sacral portion of the spinal canal.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dorsal Penile Block Anesthesia
Description: Anesthesia will be delivered via inhalation induction with air/nitrous oxide and sevoflurane, and injection of 0.25% bupivacaine without epinephrine into the dorsal portion of the penis.
Study: NCT03495063

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Natural Caffeine
Description: Consumption of 400mg of natural caffeine

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Synthetic Caffeine
Description: Consumption of 400mg of synthetic caffeine
Study: NCT02869763

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 10 g ethanol
Description: 31 mL of Vodka Absolut® diluted in 369 mL of lemon flavored-water (LFW) Fontvella®.~A total volume of 400 mL of the drink will be administered, distributed in three 133 mL cool glasses. Administration of ethanol beverage will be controlled: participants will have 5 minutes to drink each glass.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 20 g ethanol
Description: 63 mL of Vodka Absolut® diluted in 337 mL of lemon flavored-water (LFW) Fontvella®.~A total volume of 400 mL of the drink will be administered, distributed in three 133 mL cool glasses. Administration of ethanol beverage will be controlled: participants will have 5 minutes to drink each glass.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: 400 mL of lemon flavored-water Fontvella®. A total volume of 400 mL of the drink will be administered, distributed in three 133 mL cool glasses. The administration will be controlled: participants will have 5 minutes to drink each glass.
Study: NCT01428843

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FERRISAT
Description: A single infusion of 50 mg/ml of Ferrisat during inclusion visit.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: A single infusion of Glucose 5% solution during inclusion visit
Study: NCT04193787

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EPIC-P
Description: EPIC-P is a brief, bio-behavioral intervention based on the information-motivation-behavioral skills (IMB) model framework, which integrates i) a biomedical component (i.e., PrEP), ii) behavioral components (i.e., drug- and sex-related primary HIV prevention), and iii) mHealth technology (i.e., text messaging PrEP reminders).
Study: NCT01227837

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: placebo
Description: placebo given to patients

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omga3
Description: use of omega 3
Study: NCT01802905

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: in depth genomic sequencing
Description: Fresh tumour biopsies and matched normal specimens (blood and surrounding tissue) and when possible archival pretreatment specimens, will undergo in depth DNA and RNA sequencing and analysis on an oncogene panel.
Study: NCT01460459

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: a specific frequency of SMBG
Description: Patients are instructed to measure their blood glucose concentrations 4 times per day (pre-prandial and before bedtime:~high frequency: one day weekly middle frequency:one day per two weeks low frequency:one day monthly

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: a specific frequency of SMBG
Description: Patients are instructed to measure their blood glucose concentrations 4 times per day (pre-prandial and before bedtime:~high frequency: one day weekly middle frequency:one day per two weeks low frequency:one day monthly

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: a specific frequency of SMBG
Description: Patients are instructed to measure their blood glucose concentrations 4 times per day (pre-prandial and before bedtime:~high frequency: one day weekly middle frequency:one day per two weeks low frequency:one day monthly
Study: NCT03405675

Intervention type: OTHER
Intervention: SLAS 1
Description: NA. Observational study, no interventions administered.

Intervention type: OTHER
Intervention: SLAS 2
Description: NA. Observational study, no interventions administered.
Study: NCT03492749

Intervention type: DIAGNOSTIC_TEST
Intervention: Saliva monitoring
Description: The first objective of this project is to verify the feasibility of using the analysis of salivary concentration of BU during individual adjustments of this drug in the period that precedes HSCT

Intervention type: DIAGNOSTIC_TEST
Intervention: Saliva monitoring
Description: The first objective of this project is to verify the feasibility of using the analysis of salivary concentration of BU during individual adjustments of this drug in the period that precedes HSCT
Study: NCT04468945

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mirror box therapy
Description: * Patients in Task-specific mirror box therapy group will receive therapy for 30 min/day, 3 times/week for 6 weeks.~* The patient is seated close to a table a mirror (33\*35 cm) was placed vertically. The involved hand was placed behind the mirror and uninvolved in front of the mirror.~* The subject is asked to transfer small cubes from the middle position to the lateral side, placing pegs in holes and taking them out, turning over paper cards, placing steel needles in holes, stacking blocks, and putting glass on a shelf.~* During the sessions, subjects will be asked to try and do the activity on the unaffected side and asked to do some movement with the paretic hand simultaneously.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Repetitive Facilitation Exercise
Description: * The patients in the control group will receive Repetitive Facilitation Exercise for 30 min/day, 3 times/week for 6 weeks.~* Repetitive facilitative techniques were used to elicit movement of the shoulder, elbow, wrist, and fingers in a manner designed to minimize synergistic movements.~* Participants were directed to concentrate on generating movement on the joint being treated while avoiding contraction of non-targeted muscles.~* Therapists provided verbal directions with commands such as bend/straighten or one, two, three.~* Participant efforts were supplemented as necessary to achieve a full range of motion (ROM)
Study: NCT04761900

Intervention type: DIAGNOSTIC_TEST
Intervention: the differences of MAFLD and MAFLD-simplified definitions were compared in predicting metabolic diseases

Intervention type: DIAGNOSTIC_TEST
Intervention: the differences of MAFLD and MAFLD-simplified definitions were compared in predicting metabolic diseases

Intervention type: DIAGNOSTIC_TEST
Intervention: the differences of MAFLD and MAFLD-simplified definitions were compared in predicting metabolic diseases
Study: NCT03457870

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intermittent Energy Restriction
Description: Dietary advice to follow a 5:2 diet.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chewing
Description: Asked to chew 1 piece of gum for 10 minutes 3 times a day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chewing + Intermittent Energy Restriction
Description: Dietary advice to follow a 5:2 diet. Asked to chew 1 piece of gum for 10 minutes 3 times a day.
Study: NCT02077101

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire

Intervention type: OTHER
Group type: OTHER
Intervention: Interview
Study: NCT02997293

Intervention type: OTHER
Intervention: Enhanced Recovery protocol
Description: The Enhanced Recovery protocol focuses on many areas or perioperative care, including non-narcotic pain management, optimization of fluid balance throughout the perioperative course, early eating, ambulation, early removal of drains postoperatively, and preoperative patient education.

Intervention type: OTHER
Intervention: Enhanced Recovery protocol
Description: The Enhanced Recovery protocol focuses on many areas or perioperative care, including non-narcotic pain management, optimization of fluid balance throughout the perioperative course, early eating, ambulation, early removal of drains postoperatively, and preoperative patient education.
Study: NCT01835691

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D2 (ergocalciferol)
Description: 50,000 units once a week for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (cholecalciferol)
Description: 50,000 units once a week for 12 weeks
Study: NCT03657602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kyleena Intrauterine System
Description: Participant will be randomly allocated to this intervention

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirena Intrauterine System
Description: Participant will be randomly allocated to this intervention
Study: NCT03389373

Intervention type: DEVICE
Group type: OTHER
Intervention: GC Strep Mutans Saliva Sampling
Description: Children who match inclusion criteria will have a saliva sample obtained which will act as a proxy for bacterial levels.
Study: NCT02762643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DP-R213
Description: Investigational product is prescribed to all of randomized subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DP-R213
Description: Investigational product is prescribed to all of randomized subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raloxifene
Description: Investigational product is prescribed to all of randomized subjects
Study: NCT02254772

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: A dose of 10 mg in cohort 1 or 25mg in cohort 2 via intratumoral injection on day 2, week 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SD-101
Description: Started on day 2 week 1, then once every week x 4 successive weeks for a total of 5 injections.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Undergo low-dose radiation therapy to 1 site of disease
Study: NCT01202500

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: reducing treatment to 3 months
Description: The treatment will be stopped after 3 months

Intervention type: PROCEDURE
Group type: OTHER
Intervention: registered length of treatment
Description: The treatment procedure will follow the actual recommandation
Study: NCT00928434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Degarelix treatment provided for first seven months (one starting dose and six maintenance doses) followed by no treatment for next seven months period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Degarelix treatment provided for complete study period (one starting dose and 13 maintenance doses).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide
Description: Leuprolide treatment for complete study period (one starting dose and 5 maintenance doses of 3-month depot each)
Study: NCT02168959

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine
Description: This drug is standard of care. The point of the study is to see if this method will yield better pain scores and improved patient satisfaction vs. non-nerve block. Simply: prospective observation of two standard methods.
Study: NCT03255369

Intervention type: OTHER
Intervention: Child exposed Zika virus proved
Description: There will be applied Bayley Teste 3rd edition

Intervention type: OTHER
Intervention: Child exposed Zika virus proved
Description: There will be applied Bayley Teste 3rd edition

Intervention type: OTHER
Intervention: Child exposed Zika virus proved
Description: There will be applied Bayley Teste 3rd edition
Study: NCT02138565

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastric by-pass surgery
Study: NCT02900352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zonisamide
Description: Titration of dose to 500mg oral, daily, over 8 weeks, then 7 weeks of treatment at that dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00653393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranylcypromine
Description: Tablets, 10 mg, single-dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Parnate
Description: Tablets, 10 mg, single-dose
Study: NCT02354287

Intervention type: PROCEDURE
Intervention: Cold forceps polypectomy with pre lift
Description: Polyps ≤7mm will be included in the study if deemed appropriate by the colonoscopist..~These polyps will be resected with cold forceps after pre injection into the submucosa with a few millilitres of pre injection solution (19 ml gelofusine, 1ml 1:10000 adrenaline and 1ml indigo carmine). Polyps are grasped with the cold forceps and pulled away from the rest of the colonic mucosa. Attempt will be made to remove polyps with single attempt with the forceps however several grasps may be required for complete visual resection of the polyp.~The polypectomy site and a 5mm rim of normal appearing tissue will then be resected with endomucosal resection (EMR) using conventional snare method. This is to ascertain if there is any residual polyp tissue.
Study: NCT03017807

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Anti-EGFr Antibody
Description: Low-dose level patients received cetuximab initial dose 100 mg/m2 and 4 weeks later 250 mg/m2 weekly maintenance to the disease progression or unacceptable toxicity or death or withdraw informed consent.High-dose level patients received cetuximab initial dose 400 mg/m2 and 4 weeks later loading 400 mg/m2 and 250 mg/m2 weekly maintenance to the disease progression or unacceptable toxicity or death or withdraw informed consent.
Study: NCT03345641

Intervention type: OTHER
Intervention: describe precocious maternal impressions when confronting the premature birth of her infant
Study: NCT03606811

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fluroscopic guided block
Description: SHPB will be done Fluoroscopic-guided (the posterior oblique trajectory technique.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: double modality (ultrasound and fluroscopic) guided block
Description: SHPB will be done using our described new technique of performing the modified Mishra technique by injecting 3-5 ml of contrast media (lohexol=omnipaque) after getting the target position. Then C-arm pictures will be checked (both P-A \& dead lateral)
Study: NCT02625701

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Goal-directed therapy
Description: Optimize CO with additional fluid according to dynamic indices (PPV, SVV, Stroke volume)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Restrictive fluid therapy
Description: Keep normovolemia with basal crystalloids infusion (3-6 ml/kg/h) and compensate additional fluid losses with colloids or crystalloids.
Study: NCT04772066

Intervention type: OTHER
Intervention: Measure of medication adherence
Description: Measure of medication adherence

Intervention type: OTHER
Intervention: Measure of medication adherence
Description: Measure of medication adherence
Study: NCT00468117

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Islet transplantation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Antithymocyte Globulin
Description: Participants will begin receiving ATG 2 days prior to the initial islet transplant and will continue to receive ATG until Day 2 post-transplant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daclizumab or Basiliximab
Description: Daclizumab or Basiliximab will be used for subsequent transplants.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Etanercept will be given on the day of transplant and on Days 3, 7, and 10 post-transplant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogenic human purified pancreatic islets
Description: 200 ml suspension of allogenic human purified islets
Study: NCT01091922

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Low flavanol cocoa beverage
Description: 23 mg of total flavanols from cocoa

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High flavanol cocoa beverage
Description: 495 mg of total flavanols from cocoa
Study: NCT01040949

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: couple-based counseling for smoking cessation plus self-help smoking cessation guide
Description: Culturally sensitive couple-based counseling for smoking cessation plus self-help smoking cessation guide in Latino men with pregnant partners

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Guia -a self help smoking cessation guide
Description: A culturally sensitive smoking cessation self help program for Latinos
Study: NCT03671070

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Description: IV Low dose Boluses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Traditional management of shock
Description: 1. Initial resuscitation: Push boluses of 20 cc/kg isotonic saline or colloid up to and over 60 cc/kg until perfusion improves or unless rales or hepatomegaly develop~2. Fluid refractory shock: Begin inotrope IV/IO. Use atropine/ketamine IV/IO/IM to obtain central access and airway if needed. Reverse cold shock by titrating central dopamine or, if resistant, titrate central epinephrine. Reverse warm shock by titrating central norepinephrine.~3. Catecholamine resistant shock: Begin hydrocortisone if at risk for absolute adrenal insufficiency.
Study: NCT02071459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Threo DOPS
Description: initial dose titration period (4 weeks) followed by 8 weeks at the max tolerated dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: initial period (4 weeks) followed by 8 weeks
Study: NCT00785356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proellex 25 mg
Description: Proellex 25 mg, 1 - 25 mg capsule and 1 placebo capsule daily for 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proellex 50 mg
Description: Proellex 50 mg, 2 - 25 mg capsules daily for 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 2 capsules daily for 3 months
Study: NCT00468585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study: NCT02773498

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional TESE
Description: usual procedure for sperm extraction

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Micro TESE
Description: procedure of extraction is performed under the operating microscope
Study: NCT04414007

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet+ home-based cardiac rehabilitation
Description: The Internet+ home-based cardiac rehabilitation group receive home-based cardiac rehabilitation program through Internet platform and intelligent wearable devices .

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation
Description: We provide patients with cardiac rehabilitation manuals and exercise logs. 4 weeks after ablation，Patients have CPET.Their exercise prescription was made according to CPET .The patients have rehabilitation training at home and recorded their exercise data including exercise time、type、frequency and average heart rate.
Study: NCT01477762

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: One tablet of 0.5 mg dexamethasone will be taken ten hours prior to completing study assessments.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: One tablet of 0.5 mg dexamethasone will be taken ten hours prior to completing study assessments.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: One placebo tablet will be taken ten hours prior to completing study assessments.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One placebo tablet will be taken ten hours prior to completing study assessments.
Study: NCT02184104

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine
Study: NCT00434824

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral testosterone undecanoate (Andriol)
Description: treatment for 12 months with oral TU 80 mg/d, oral TU 160 mg/d or oral TU 240 mg/d in divided doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: treatment for 12 months with placebo in divided doses
Study: NCT04818099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine 10 mg
Description: Vortioxetine will be used with a dosage of 10mg once a day, for 2 months.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be used with a dosage of one tablet once a day for 2 months.
Study: NCT02762643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raloxifene
Description: Investigational product is prescribed to all of randomized subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecaliferol
Description: Investigational product is prescribed to all of randomized subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecaliferol
Description: Investigational product is prescribed to all of randomized subjects
Study: NCT03374943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KB004
Description: KB004 is a recombinant, non-fucosylated, IgG1κ (human f-allotype) monoclonal antibody targeting the extracellular ligand binding domain of the EphA3 (ephrin receptor) tyrosine kinase
Study: NCT01809756

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Caphosol
Description: Caphosol 4 times a day
Study: NCT03336359

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Tandem colonoscopy
Description: Different image enhanced endoscopy systems

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Tandem colonoscopy
Description: Different image enhanced endoscopy systems